DB-3Q
Phase 2Biologic
DB-3Q is one of 52 biologic programs targeting Crohn's Disease. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
67 competitors in Crohn's Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Entyvio
TakedaApproved
Humira
RRanbaxy Laboratories Limited
Approved
Omvoh
Eli LillyApproved
Trexall
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Mycobutin
PfizerApproved
Opzelura
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DB-3Q. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- DDirect Biologics, LLC